Jump to content

Draft:Oswald Vander Veken Prize

From Wikipedia, the free encyclopedia


The Oswald Vander Veken Prize is a European price awarded by the Research Foundation – Flanders (FWO) and the Fonds de la Recherche Scientifique-FNRS (F.R.S.-FNRS) every three years since 1987 to acknowledge an original contribution to knowledge about the tumours of the locomotor system (Bone-and soft tissue tumours [1]), their aetiology, prevention, diagnosis and/or treatment. The award is given to a researcher or a research team of a maximum of three researchers affiliated with a university in the European Economic Area or Switzerland.[2] The price is named after a patient who died because of a rare malignant tumour of the skeleton. As a remembrance of him, his family started this prize.[3] The price is intended to highlight this type of unusual cancer, as despite all research on these tumours, the prognosis of these patients is not very good. [4][5] It is the only European price in this area of study. It is considered a prestigious award for this type of research and the most prestigious prize for the subject area in Europe. It has celebrated previous winners like:

  • Claude CAREL, Centre Universitaire de Dijon, University of Burgundy (F) (1987): "Anomalies chromosomiques spécifiques dans des tumeurs solides des tissus mous."
  • Christopher D. M. Fletcher, (St Thomas' Hospital; London (GB) (1990): "Etude des tumeurs des tissus mous au moyen de techniques clinico-pathologiques et biologiques moléculaires et développement d'un sarcome des tissus mous à des fins de diagnostic et de traitement."
  • Gilles Thomas, Directeur de Recherches du C.N.R.S., Curie Institute, Paris (F) (1993): "Clonage des points de cassure de la translocation chromosomique t(11;22) du sarcome d'Ewing, identification des genes impliques et elucidation des consequences structurales de leurs rearrangements."
  • Colin Cooper, Institute of Cancer Research, Surrey (GB) (1996): "Molecular analysis of the t(x;18) and t(9;22) sarcoma translocations: determination of the normal functions of the SYT, SSX1, SSX2 and CHN proteins and appraisal of their use in the management of synovial sarcomas and chondrosarcomas."
  • Alexander M.M. EGGERMONT, Erasmus Universiteit, Rotterdam (NL) (2002): "TNF-based isolated limb perfusion for limb salvage for locally advanced extremity soft tissue sarcomas, and other irresectable tumours."
  • Nils MANDAHL, Fredrik MERTENS, and Ioannis PANAGOPOULOS, Lund University Hospital (SE) (2005): "Cytogenetic and molecular genetic investigation of bone and soft tissue tumours."
  • Pancras C.W. HOGENDOORN, Universiteit Leiden (NL) (2008): "Molecular tumour pathology of tumours of the musculoskeletal system esp. Cartilaginous Tumours".
  • Katia SCOTLANDI, Istituto Ortopedico Rizzoli di Bologna (Italy) (2011): "Development of new bullets against Ewing's sarcoma: academy builds its own industry."
  • Patrick SCHÖFFSKI, KU Leuven (B) 2014: "Activity of Eribulin mesylate in patients with soft tissue sarcoma: a phase II study in four independent histological subtypes (and related work)."
  • Dominique HEYMANN, University of Nantes (F) (2017): "The heterogeneity of the tumour microenvironment as a source of therapeutic targets in bone sarcomas."
  • Anabelle DECOTTIGNIES, UCLouvain (B) (2020): "The ALTernative mechanism of telomere maintenance: a promising target for tumours of the locomotor apparatus?"
  • Thomas SCHUBERT, Robin EVRARD and Pierre-Louis DOCQUIER, UCLouvain (B) (2023): "Improving bone sarcoma surgery."

References

[edit]
  1. ^ L.B. Rozeman, A.M. Cleton-Jansen, P.C.W.Hogendoorn. Pathology of primary malignant bone and cartilage tumours. Int. Orthopaedics 2006;30:437-444
  2. ^ https://www.frs-fnrs.be/docs/Prix/FRS-FNRS_Prix_Oswald_Vander_Veken_EN.pdf
  3. ^ FWO jaarboek 2010;36-37
  4. ^ https://www.cancerdata.nhs.uk/getdataout/sarcoma
  5. ^ https://seer.cancer.gov/statfacts/html/bones.html
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Oswald_Vander_Veken_Prize&oldid=1283574178"